Podcast - Quality by Design: Where We Stand Now - - BioPharm International

ADVERTISEMENT

Podcast - Quality by Design: Where We Stand Now





Add this Podcast feed to your media player



Quality by Design: Where We Stand Now

On what aspects of Quality by Design is there now consensus within the industry and regulatory bodies, and what remains to be sorted out?

Join Laura Bush, Editor in Chief of BioPharm International and John Towns, Senior Director of Global CMC Regulatory Affairs at Eli Lilly, as they discuss the current state of QbD.



Click here to go to the main podcast page >>>

Related Links:
Quality by Design for Biotechnology Products—Part 1: A PhRMA Working Group's advice on applying QbD to biotech.

Convincing the Skeptics

Quality by Design A-MAb Case Study Challenges Conventional Thinking
blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here